{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 participant had response, therefore median and 95% Confidence Interval were not calculable.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Only 3 participants had events, therefore median was not calculated. The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG001","lowerLimit":"17.87","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"DOR is defined as elapsed time from the first evidence of CR, PR, MR or MinR until date of progression of disease (PD). EBMT RC used for MM. CR: no serum/urine M protein for 6 wk, \\<5% PCBM, no LBL size/number increase, no STPC; PR: met some CR criteria plus maintain for 6 wk ≥50% SPEP and PCBM decrease, either decrease of ≥90% or \\<200 mg LCE, ≥50% STPC size decrease; MR: met some PR criteria plus maintain for 6 wk decrease of: 25-49% SPEP, 50-89% 24 hour urinary LCE, 25-49% PCBM, 25-49% STPC size. PD: \\>25% increase in SPEP, 24 hour urinary LCE, PCBM, STPC size increase, new bone lesion or STPC. IWWM RC used for WM. CR: no serum M protein, malignant cells in BM, or lymphadenopathy/organomegaly; PR: ≥50% IgM and A/O decrease; no new WM symptoms. MinR: ≥25% to \\<50% IgM decrease, no A/O progression; no cytopenias or clinical of WM symptoms. PD: \\>25% IgM increase, progression of clinical findings or symptoms. For participants who had no PD, DOR was censored at their last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.","id":"OG000","title":"Multiple Myeloma (MM)"},{"description":"Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.","id":"OG001","title":"Waldenstrom's Macroglobulinemia (WM)"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one dose of the study drug and had complete response (CR) or partial response (PR) or minimal response (MR) or minor response (MinR). The numbers of participants censored are 1 (MM) and 13 (WM).","reportingStatus":"POSTED","timeFrame":"Time of response to time of measured progressive disease up to 38.37 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}